PRODUCT MONOGRAPH. naproxen. 375 & 500 mg Enteric-Coated Tablet 750 mg Sustained-Release Tablet

Similar documents
Accel-Celecoxib Product Monograph Page 52 of 56

PRODUCT MONOGRAPH. Pr TORADOL. ketorolac tromethamine 10 mg tablets. ketorolac tromethamine injection 10 mg/ml intramuscular injection

IMPORTANT: PLEASE READ

PRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic

PART III: CONSUMER INFORMATION

Sandoz Diclofenac and Sandoz Diclofenac SR Page 34 of 38

Sandoz Diclofenac and Sandoz Diclofenac SR Page 34 of 38

IMPORTANT: PLEASE READ

PRODUCT MONOGRAPH. Pr KYTRIL. granisetron hydrochloride tablets. 1 mg granisetron as hydrochloride. Manufacture Standard

PRODUCT MONOGRAPH TARCEVA. erlotinib hydrochloride tablets. erlotinib 25, 100, 150 mg

PATIENT MEDICATION INFORMATION

PRODUCT MONOGRAPH. capecitabine. Tablets 150 mg and 500 mg. Manufacturer s Standard. Antineoplastic Agent. Date of Revision: February 10, 2017

PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

LECTOPAM PRODUCT MONOGRAPH. bromazepam. 3 mg and 6 mg Tablets. Anxiolytic - Sedative. Date of Revision: September 6, 2018

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR

Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

PRODUCT MONOGRAPH. Pr PROLOPA. levodopa and benserazide capsules. 50 mg mg, 100 mg - 25 mg, 200 mg - 50mg. Pharmaceutical standard: professed

PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. Pantoprazole Magnesium Enteric-Coated Tablets

in people who have heart disease

IMPORTANT: PLEASE READ

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. PRINIVIL (lisinopril tablets, Merck Standard)

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ALECENSARO. alectinib (as alectinib hydrochloride) Capsule, 150 mg

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (omeprazole delayed release capsules USP)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. rabeprazole sodium tablets

This leaflet answers some common questions about NAPROSYN tablets. It does not contain all the available information.

Before you take PROXEN SR. When you must not take it

NAPROSYN pronounced nap-row-sin

Before you take ANAPROX. When you must not take it

PROXEN SR contains the active ingredient naproxen

REDUCE THE HURT REDUCE THE HARM

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

PATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)

OXEZE TURBUHALER formoterol fumarate dihydrate

Migraine Relief Film-coated Tablets ibuprofen lysine

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET

Etopan XL 600 mg tablets

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules

NALGESIN NALGESIN S 275 mg Film-coated tablets NALGESIN F 500 mg Film-coated tablets

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ. fenofibrate, NanoCrystal formulation tablets

Before you take Celebrex. When you must not take it

It does not contain all the available information. It does not take the place of talking to your doctor or nurse.

Your doctor may have prescribed MOVALIS for another reason. Ask your doctor if you have any questions about why MOVALIS has been prescribed for you.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] Mepolizumab for Injection

Patient Information Leaflet UNITED KINGDOM Feldene IM Intramuscular Injection 20mg/ml piroxicam

IMPORTANT: PLEASE READ

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.

Ceclor CD cefaclor monohydrate sustained release tablets

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules

PART III: CONSUMER INFORMATION

ARTHREXIN indometacin

Advil* 200mg Tablets Ibuprofen

TORADOL Tablets contains the active ingredient ketorolac trometamol

READ THIS FOR SAFE AND EFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION. Lansoprazole delayed release capsules

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. ERYC Erythromycin delayed release capsules USP

Methotrexate Injection USP Page 39 of 43

Package leaflet: Information for the patient. Melox 10 mg/ml solution for injection meloxicam

Bisacodyl Laxative (Pharmacy Health)

PART III: CONSUMER INFORMATION

PATIENT INFORMATION LEAFLET SINTAIR RANGE

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION 1. Esomeprazole Magnesium

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

Consumer Medicine Information DICLAX SR. What is in this leaflet. What DICLAX SR is used for. Diclofenac Sodium modified release

PRODUCT MONOGRAPH. Pr TAMIFLU. oseltamivir capsule 30 mg, 45 mg and 75 mg oseltamivir (as oseltamivir phosphate)

PATIENT INFORMATION LEAFLET DYNARB RANGE

PART III: CONSUMER INFORMATION

PRODUCT MONOGRAPH. obinutuzumab. 25 mg/ml Concentrate for Solution for Infusion. Professed Standard. Antineoplastic

Before you take CELECOXIB SANDOZ. When you must not take it

Package Leaflet: Information for the User. Read all of this leaflet carefully because it contains important information for you.

PART III: CONSUMER INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. AZITHROMYCIN Azithromycin Tablets

Ask your healthcare provider if SPRIX (ketorolac tromethamine) Nasal Spray is right for you

ONBREZ BREEZHALER should only be used to treat COPD.

What is in this leaflet

NEW ZEALAND CONSUMER MEDICINE INFORMATION

Patient & Family Guide. Aspirin.

NEOFEN 60 mg suppository

Package Leaflet : Information for the patient

Full prescribing information is available to doctors and pharmacists on request.

Amizide contains the active ingredients hydrochlorothiazide and amiloride hydrochloride

Before you take ARTHREXIN. When you must not take it

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. omeprazole delayed release capsules USP

INFORMATION FOR THE CONSUMER

SANDOMIGRAN. 0.5mg tablet Pizotifen malate

Before you take it. When you must not take it

Patient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets

of LDL and HDL cholesterol.

COMPOSITION: Each film-coated tablet contains 500mg mefenamic acid. Also includes sunset yellow E110. See leaflet for further information.

Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets

Patient Information Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg Rx only

OXEZE TURBUHALER formoterol fumarate dihydrate dry powder for oral inhalation

Orudis Suppositories Ketoprofen

PART III: CONSUMER INFORMATION. topiramate tablets

Transcription:

PRODUCT MONOGRAPH Pr NAPROSYN naproxen 375 & 500 mg Enteric-Coated Tablet 750 mg Sustained-Release Tablet Pharmaceutical Standard: Professed (Sustained-Release Tablet), House (Enteric-Coated Tablet) Non-Steroidal Anti-Inflammatory Drug (NSAID) Hoffmann-La Roche Limited 7070 Mississauga Road Mississauga, Ontario, Canada L5N 5M8 www.rochecanada.com Date of Revision: October 9, 2014 Copyright 1974 2014 by Hoffmann-La Roche Ltd. Submission Control No: 176980 NAPROSYN is a registered trade-mark of Syntex Pharmaceuticals International Limited, used under license. Page 1 of 6

Table of Contents PART III: CONSUMER INFORMATION...3 Page 2 of 6

PART III: CONSUMER INFORMATION Pr NAPROSYN naproxen Read this information each time you refill your prescription in case new information has been added. This leaflet is a summary designed specifically for you to read. It will NOT tell you everything about NAPROSYN. See your health care provider and pharmacist regularly and ask them questions about your health and any medications you take. ABOUT THIS MEDICATION What the medication is used for: Your health care provider has prescribed NAPROSYN for you for one or more of the following medical conditions: For the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. For the relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in sprains and strains and primary dysmenorrhea. What it does: NAPROSYN (naproxen), as a non-steroidal anti-inflammatory drug (NSAID), can reduce the chemicals produced by your body which cause pain and swelling. NAPROSYN, as a non-steroidal anti-inflammatory drug (NSAID), does NOT cure your illness or prevent it from getting worse. NAPROSYN can only relieve pain and reduce swelling as long as you continue to take it. When it should not be used: DO NOT TAKE NAPROSYN if you have any of the following medical conditions: Heart bypass surgery (planning to have or recently had) Severe, uncontrolled heart failure Bleeding in the brain or other bleeding disorders Current pregnancy (after 28 weeks of pregnancy) Currently breastfeeding (or planning to breastfeed) Allergy to ASA (Acetylsalicylic Acid) or other NSAIDs (Non-steroidal Anti-Inflammatory Drugs) Ulcer (active) Bleeding from the stomach or gut (active) Inflammatory bowel disease (Crohn s Disease or Ulcerative Colitis) Liver disease (active or severe) Kidney disease (severe or worsening) High potassium in the blood Patients who took a drug in the same class as NAPROSYN after a type of heart surgery (coronary artery bypass grafting (CABG)) were more likely to have heart attacks, strokes, blood clots in the leg(s) or lung(s), and infections or other complications than those who did NOT take that drug. NAPROSYN should NOT be used in patients under 18 years of age since the safety and effectiveness have NOT been established. What the medicinal ingredient is: naproxen What the important non-medicinal ingredients are: NAPROSYN (Sustained Release Tablets) contain the following non-medicinal ingredients: hydroxypropyl methylcellulose, magnesium stearate, FD&C Yellow No. 6. NAPROSYN (Enteric Coated Tablets) contain the following nonmedicinal ingredients: povidone K-90, croscarmellose sodium, magnesium stearate, methacrylic acid copolymer Type C, talc, sodium hydroxide, triethyl citrate. What dosage forms it comes in: NAPROSYN is available as: enteric coated tablets (375 mg and 500 mg); sustained release tablet (750 mg). WARNINGS AND PRECAUTIONS If you have, or previously had, any of the following medical conditions, see your health care provider to discuss treatment options other than NAPROSYN: Heart Attack or Angina Stroke or Mini-stroke Loss of Vision Current Pregnancy (less than 28 weeks) Congestive Heart Failure Before taking this medication, tell your health care provider if you have any of the following: High blood pressure High cholesterol Diabetes mellitus or on a low sugar diet Atherosclerosis Poor circulation to your extremities Smoker or ex-smoker Kidney disease or urine problems Previous ulcer or bleeding from the stomach or gut (small or large intestine) Previous bleeding in the brain Bleeding problems Family history of allergy to NSAIDs, such as acetylsalicylic acid (ASA), celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, sulindac, tenoxicam, tiaprofenic acid, tolmetin, or valdecoxib (NOT a complete list) Page 3 of 6

Family history of asthma, nasal polyps, long-term swelling of the sinus (chronic sinusitis) or hives Also, before taking this medication, tell your health care provider if you are planning to get pregnant. While taking this medication: tell any other doctor, dentist, pharmacist or other health care professional that you see, that you are taking this medication, especially if you are planning to have heart surgery; do NOT drink alcoholic beverages while taking this medication because you would be more likely to develop stomach problems; fertility may be decreased. The use of NAPROSYN is not recommended in women trying to get pregnant. In women who have difficulty conceiving, stopping NAPROSYN should be considered. INTERACTIONS WITH THIS MEDICATION Talk to your health care provider and pharmacist if you are taking any other medication (prescription or non-prescription) such as any of the following (NOT a complete list): Acetylsalicylic Acid (ASA) or other NSAIDs o e.g. ASA, celecoxib, diclofenac, ibuprofen, indomethacin, ketorolac, meloxicam, naproxen Antacids Antidepressants o Selective Serotonin Reuptake Inhibitors (SSRIs) e.g. citalopram, fluoxetine, paroxetine, sertraline Blood pressure medications o o ACE (angiotensin converting enzyme) inhibitors e.g. enalapril, lisinopril, perindopril, ramipril ARBs (angiotensin II receptor blockers) e.g. candesartan, irbesartan, losartan, valsartan Blood thinners o e.g. warfarin, ASA, clopidogrel Corticosteroids (including glucocorticoids) o e.g. prednisone Cyclosporin Digoxin Diuretics o e.g. furosemide, hydrochlorothiazide Lithium Methotrexate Oral contraceptives Oral hypoglycemics (diabetes medications) Tacrolimus Your health care provider may prescribe low dose ASA (acetylsalicylic acid) as a blood thinner to reduce your risk of having a heart attack or stroke while you are taking NAPROSYN. Take only the amount of ASA prescribed by your health care provider. You are more likely to upset or damage your stomach if you take both NAPROSYN and ASA than if you took NAPROSYN alone. PROPER USE OF THIS MEDICATION NAPROSYN is intended for use in patients greater than 18 years of age for the shortest possible duration. Usual dose: 18 years of age and older: Medical Condition Starting Dose Maximum Dose (per day) Osteoarthritis/Rheumatoid Arthritis/Ankylosing Spondylitis 250 mg* twice daily 1000 mg (given as 500 mg twice Analgesia/Musculoskeletal Injuries Dysmenorrhea 250 mg* three times daily 500 mg initial dose then 250 mg* every 6-8 hours daily) 1000 mg (given as 500 mg twice daily) 1250 mg (given in divided doses) *Note: NAPROSYN (enteric coated) 250 mg tablets are not marketed by Roche in Canada. Other 250 mg naproxen formulations are available for the 250 mg tablet starting dose. Do not increase the dose above the starting dose unless directed by your doctor. Take NAPROSYN only as directed by your health care provider. Do NOT take more of it, do NOT take it more often and do NOT take it for a longer period of time than your health care provider recommended. If possible, you should take the lowest dose of this medication for the shortest time period. Taking too much NAPROSYN may increase your chances of unwanted and sometimes dangerous side effects, especially if you are elderly, have other diseases or take other medications. If you will be using NAPROSYN for more than 7 days, see your health care provider regularly to discuss whether this medicine is working for you and if it is causing you any unwanted effects. This medication has been prescribed specifically for you. Do NOT give it to anyone else. It may harm them, even if their symptoms seem to be similar to yours. NAPROSYN should not be used in patients under 18 years of age since safety and effectiveness have NOT been established. NAPROSYN tablets should be swallowed with food or milk. NAPROSYN (sustained release) and NAPROSYN (enteric coated) tablets should be swallowed whole; do not split, chew, or crush them. Page 4 of 6

Missed Dose: It may be a good idea to ask your doctor or pharmacist ahead of time what to do about missed doses. If you forget to take a dose of NAPROSYN take it as soon as possible, then just carry on with the regular times you take your medication. If you remember your missed dose close to the time of your next dose, do not take the missed dose. Overdose: In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms. SIDE EFFECTS AND WHAT TO DO ABOUT THEM NAPROSYN may cause some side effects, especially when used for a long time or in large doses. When these side effects occur, you may require medical attention. Report all symptoms or side effects to your health care provider. NAPROSYN may cause you to become drowsy or tired. Be careful about driving or participating in activities that require you to be alert. If you become drowsy, dizzy or light-headed after taking NAPROSYN, do NOT drive or operate machinery. NAPROSYN may cause you to become more sensitive to sunlight. Any exposure to sunlight or sunlamps may cause sunburn, skin blisters, skin rash, redness, itching or discolouration, or vision changes. If you have a reaction from the sun, check with your health care provider. Check with your health care provider IMMEDIATELY if you develop chills, fever, muscle aches or pains, or other flu-like symptoms, especially if they occur before or together with a skin rash. These symptoms may be the first signs of a SERIOUS ALLERGIC REACTION to this medication. Symptom SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM Bloody or black tarry stools STOP taking NAPROSYN and get emergency medical attention IMMEDIATELY Stop taking NAPROSYN and talk to your physician or pharmacist Symptom SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM Any change in the amount or colour of your urine (red or brown) Any pain or difficulty experienced while urinating Swelling of the feet, lower legs; weight gain Vomiting or persistent indigestion, nausea, stomach pain or diarrhea Yellow discolouration of the skin or eyes, with or without itchy skin STOP taking NAPROSYN and get emergency medical attention IMMEDIATELY Stop taking NAPROSYN and talk to your physician or pharmacist Malaise, fatigue, loss of appetite Headaches, stiff neck Mental confusion, depression Dizziness, lightheadedness Hearing problems This is NOT a complete list of side effects. If you develop any other symptoms while taking NAPROSYN, see your health care provider. HOW TO STORE IT NAPROSYN (sustained release tablets) and NAPROSYN (enteric coated tablets): Store at room temperature (15-30 C). Store in a dry place. Do NOT keep outdated medicine or medicine no longer needed. Any outdated or unused medicine should be returned to your pharmacist. Keep out of reach of children. Shortness of breath, wheezing, any trouble breathing or chest tightness Skin rash, hives, swelling or itching Blurred vision, or any visual disturbance Page 5 of 6

REPORTING SUSPECTED SIDE EFFECTS You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways: -------------------------------------------------------------------------- Report online at www.healthcanada.gc.ca/medeffect Call toll-free at 1-866-234-2345 Complete a Canada Vigilance Reporting Form and: - Fax toll-free to 1-866-678-6789, or - Mail to: Canada Vigilance Program Health Canada Postal Locator 0701D Ottawa, Ontario K1A 0K9 Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect Canada Web site at www.healthcanada.gc.ca/medeffect. NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice. MORE INFORMATION This document plus the full product monograph, prepared for health professionals can be found at: www.rochecanada.com or by contacting the sponsor, Hoffmann-La Roche Limited, at: 1-888-762-4388 (Drug Information). This leaflet was prepared by Hoffmann-La Roche Limited. Last revised: October 9, 2014 Copyright 1974 2014 by Hoffmann-La Roche Ltd. NAPROSYN is a registered trade-mark of SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED, used under license. All other trade-marks are the property of their respective owners. Hoffmann-La Roche Limited Mississauga, Ontario L5N 5M8 Page 6 of 6